Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 8/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385523 | 0.88 | KDM4E (0.71) | KDM4EBCHETP53MAPTTSHR | |
| SCHEMBL2576156 | 0.87 | BCHE (0.67) | KDM4EBCHETP53MAPT | |
| SCHEMBL11890502 | 0.86 | KDM4E (0.73) | KDM4EBCHETP53MAPTTSHR | |
| SCHEMBL1387066 | 0.85 | KDM4E (0.80) | KDM4EMAPTTSHR | |
| SCHEMBL5040634 | 0.84 | KDM4E (0.66) | KDM4EBCHETP53MAPTTSHR | |
| SCHEMBL1387031 | 0.84 | KDM4E (0.74) | KDM4ETP53MAPTTSHR | |
| SCHEMBL1386481 | 0.84 | KDM4E (0.71) | KDM4EBCHETP53TSHR | |
| SCHEMBL1384214 | 0.83 | KDM4E (0.67) | KDM4EBCHETP53MAPTTSHR | |
| SCHEMBL2581813 | 0.82 | KDM4E (0.68) | KDM4EBCHETP53MAPTTSHR | |
| SCHEMBL5037413 | 0.82 | KDM4E (0.62) | KDM4EBCHETP53MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | claimed |
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2019-01-10 | — | — | US | disclosed |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG | 2018-12-20 | — | — | US | disclosed |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-9995754-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-06-12 | — | — | US | disclosed |
| US-9970938-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2018-05-15 | — | — | US | disclosed |
| WO-2012113802-A1 | USE OF ACETYLATED TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012098208-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098207-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098203-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT1S1, AKT2 | KDM4E 3884/4885BCHE 4405/4885TP53 60/4885 |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB, TUBB1, TUBB6 | KDM4E 4206/4885BCHE 3678/4885TP53 261/4885 |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | TUBB, TUBB1, TUBB6 | KDM4E 4206/4885BCHE 3678/4885TP53 261/4885 |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | KDM4E 3884/4885BCHE 4405/4885TP53 60/4885 |
| US-10067120-B2 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB1, TUBB, TUBB6 | KDM4E 3837/4885BCHE 3103/4885TP53 103/4885 |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BUB1B, BUB1, BUB3 | KDM4E 2211/4885BCHE 2544/4885TP53 46/4885 |
| US-10006078-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT2, AKT1S1 | KDM4E 4613/4885BCHE 3268/4885TP53 69/4885 |
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | KDM4E 1039/4885BCHE 3544/4885TP53 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.